Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA expression data from normal and Malignant hematopoietic cells

ABSTRACT: This data was used to identify miRNA signatures that can be used to calssify specific leukemia types including AML, precursor B ALL, precursor T ALL, and normal hematopoietic progenitor and mature populations This data was used to identify miRNA signatures that can be used to calssify specific leukemia types including AML, precursor B ALL, precursor T ALL, and normal hematopoietic progenitor and mature populations AML cell lines and patient samples, B ALL cell lines and Patient samplest, T ALL cell lines and patient samples, norma B cells, normal granulocytes, normal monocytes, normal T cells and normal CD34+ cells were used for RNA extraction and hybridization on Affymetrix microarrays. All the AML, B ALL, T ALL cell lines were cultured in vitro under appropriate culture conditons and harvested in their log phase growth for RNA extraction. AML, B ALL, and T ALL patient samples were collected...(I assume these are the PBMCs from eitehr peripheral blood or bone marrow from patients, please confirm). Normal B cells, granulocytes, monocytes, and T cells were purified from human peripheral blood of normal healthy donors.

ORGANISM(S): Homo sapiens

SUBMITTER: Amol Shetty

PROVIDER: E-GEOD-51908 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Expression data from normal and Malignant hematopoietic cells

Project description:This data was used to determine levels of BRCA1 and BRCA2 in primary human leukemia samples. Samples were determined to be high BRCA1 and/or BRCA2 or low BRCA1 and/or BRAC2. This data was used to determine levels of BRCA1 and BRCA2 in primary human leukemia samples. Samples were determined to be high BRCA1 and/or BRCA2 or low BRCA1 and/or BRAC2. AML cell lines and patient samples, B ALL cell lines and Patient samplest, T ALL cell lines and patient samples, norma B cells, normal granulocytes, normal monocytes, normal T cells and normal CD34+ cells were used for RNA extraction and hybridization on Affymetrix microarrays. All the AML, B ALL, T ALL cell lines were cultured in vitro under appropriate culture conditons and harvested in their log phase growth for RNA extraction. AML, B ALL, and T ALL patient samples were collected...(I assume these are the PBMCs from eitehr peripheral blood or bone marrow from patients, please confirm). Normal B cells, granulocytes, monocytes, and T cells were purified from human peripheral blood of normal healthy donors.

2013-07-06 | E-GEOD-48558 | biostudies-arrayexpress

miRNA expression data from normal and Malignant hematopoietic cells

Project description:This data was used to identify miRNA signatures that can be used to calssify specific leukemia types including AML, precursor B ALL, precursor T ALL, and normal hematopoietic progenitor and mature populations This data was used to identify miRNA signatures that can be used to calssify specific leukemia types including AML, precursor B ALL, precursor T ALL, and normal hematopoietic progenitor and mature populations

2013-10-31 | GSE51908 | GEO

Expression profile of mature normal PB neutrophils

Project description:The transcriptional patterns of mature normal PB neutrophils (granulocytes) was examined and used as a control against which the transcriptional programs of cultured granulocytes and granulocytic cells lines can be compared. Keywords: Peripheral blood neutrophils

2007-06-06 | GSE6792 | GEO

Homo sapiens

Project description:Gene Expression-Based High Throughput Screening: Primary Patient AML Blasts, Normal Neutrophils, and Normal Monocytes

| PRJNA89875 | ENA

RNAseq of PRMT4KD in human cord blood derived CD34+ cells

Project description:Defining the role of epigenetic regulators in normal hematopoiesis has become critically important, as recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We have found that PRMT4, a type I arginine methyltransferase, whose function in normal and malignant hematopoiesis is unknown, is overexpressed in AML patient samples. In support of an oncogenic role for PRMT4, we find that its overexpression blocks the myeloid differentiation of human stem/progenitor cells (HSPCs) while its knockdown (KD) is sufficient to induce myeloid differentiation of HSPCs and multiple AML cell lines. Although classically thought of as a co-activator, we found that PRMT4 functions to repress the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multi-protein repressor complex that includes DPF2. As part of a feedback loop, PRMT4 expression is repressed post-transcriptionally by miR-223 during the normal differentiation process. These data reveal an unidentified role of PRMT4 in myeloid differentiation and its unexpected repressive role in transcriptional regulation. Furthermore, depletion of PRMT4 results in the differentiation of myeloid leukemia cells in vitro and their decrease proliferation in vivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia. Purified human primary CD34+ cells were transduced with lentiviruses carrying PRMT4KD or scramble control shRNAs. Total RNA was extrated. RNAseq was performed to identify target genes that are regulated by PRMT4. Experiments were performed in triplicate.

2013-12-19 | E-GEOD-46056 | biostudies-arrayexpress

Gene Expression-Based High Throughput Screening: APL Treatment with Candidate Compounds

Project description:We developed a general approach to small molecule library screening called GE-HTS (Gene Expression-Based High Throughput Screening) in which a gene expression signature is used as a surrogate for cellular states and applied it to the identification of compounds inducing the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we identified 8 that reliably induced the differentiation signature, and furthermore yielded functional evidence of bona fide differentiation. We tested several of these in duplicate replicates in blasts from a patient with APL. Also included in this data set are a collection of 6 primary patient AML cells, 3 normal neutrophils samples, and 3 normal monocyte samples. This data was used to evaluate whole genome effects of the compounds on APL cells in relation to AML versus normal neutrophils and monocytes. Keywords = Leukemia Keywords = APL Keywords = AML Keywords = chemical genomics Keywords: repeat sample

2004-01-30 | GSE976 | GEO

Growth factor independence 1 (Gfi1) regulates cell-fate decision of the bipotential granulocytic-monocytic precursor defined by the expression of CD48 as a new marker

Project description:Using bone marrow cells of GFP:Gfi1 knock in mice, we separated Gfi1-high and Gfi1-low expressing cells in the classical CD11b+, GR1-low monocytic cell fraction. We sorted CD11b+, GR1-low GFP:Gfi1-high and low cells as well as CD11b+, GR1-high granulocytes and CD11b-high, GR1-intermediate cells from Gfi1-knock-out mice for further analysis. We used Affymetrix Mouse Genome 430A 2.0 arrays (GPL8321) The study should determine how Gfi1 regulates the cell fate of monocytes/granulocytes in mice

2012-12-19 | E-GEOD-35970 | biostudies-arrayexpress

Human AML cell lines LC-MS/MS - Performance of Super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines

Project description:As a direct consequence of the high diversity of the aggressive blood cancer acute myeloid leukemia (AML), proteomic samples from patients are strongly heterogeneous, rendering their accurate relative quantification challenging. In the present study, we investigated the benefits of using a super-SILAC mix of AML derived cell lines as internal standard for quantitative shotgun studies. The Molm-13, NB4, MV4-11, THP-1, and OCI-AML3 cell lines were selected for their complementarity with regard to clinical, cytogenetic and molecular risk factors used for prognostication of AML patients. The resulting internal standard presents a high coverage of the AML proteome compared to single cell lines allied with high technical reproducibility, thus enabling its use for AML patient comparison. This was confirmed by comparing the protein regulation between the five cell lines and applying the internal standard to patient material.

2014-07-15 | PXD000441 | Pride

Homo sapiens

Project description:Detection of aberrant DNA methylation in AML cell lines compared to normal human monocytes

| PRJNA118727 | ENA

Cord blood hematopoietic cells display altered DNA methylation patterns in preterm birth

Project description:Genome-wide DNA methylation was measured using the Illumina 450K array in T cells, monocytes, granulocytes and nucleated red blood cells (nRBCs) isolated from cord blood of term and extreme preterm (<31 weeks gestational age) individuals. 36 samples in total: 5 each of T cells, monocytes, granulocytes and nRBCs from term births; and 5 T cells, 4 monocytes, 4 nRBCs and 3 granulocytes from preterm births.

2017-04-21 | GSE82084 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data